Potentilla fulgens upregulate GLUT4, AMPK, AKT and insulin in alloxan-induced diabetic mice: an in vivo and in silico study

References

• Abel, E.D., et al., 2001. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature, 409 (6821), 729–733.
   PubMed Web of Science ®Google Scholar
• Anal, J.M.H., et al., 2014. In vitro cytotoxicity of the polar extracts of Potentilla fulgens L. against human cancer cell lines: detection and isolation of bioactive phenolics. Journal of chemical and pharmaceutical research, 6, 89–95.
   Google Scholar
• Bailey, C.J. and Day, C., 2004. Metformin: its botanical background. Practical diabetes international, 21 (3), 115–117.
   Google Scholar
• Bandyopadhyay, G., et al., 2006. Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes, 55 (8), 2277–2285.
   PubMed Web of Science ®Google Scholar
• Belgardt, B.F. and Stoffel, M., 2014. SIK2 regulates insulin secretion. Nature cell biology, 16 (3), 210–212.
   PubMed Web of Science ®Google Scholar
• Berman, H.M., et al., 2000. The Protein Data Bank. Nucleic acids research, 28 (1), 235–242.
   PubMed Web of Science ®Google Scholar
• Bharti, S.K., et al., 2018. Antidiabetic phytoconstituents and their mode of action on metabolic pathways. Therapeutic advances in endocrinology and metabolism, 9 (3), 81–100.
   PubMed Web of Science ®Google Scholar
• Bolton, E.E., et al., 2008. PubChem: integrated platform of small molecules and biological activities. Annual reports in computational chemistry, 4, 217–241.
   Google Scholar
• Bradford, M.M., 1976. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein “dye” binding. Analytical biochemistry, 72, 248–254.
   PubMed Web of Science ®Google Scholar
• Brozinick, J.T., Jr., Roberts, B.R., and Dohm, L.G., 2003. Defective signaling through Akt-2 and -3 but not Akt-1 in insulin-resistant human skeletal muscle: potential role in insulin resistance. Diabetes, 52 (4), 935–941.
   PubMed Web of Science ®Google Scholar
• Brunton, L. B., Lazo, J. S., and Parker, K. L., 2005. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill.
   Google Scholar
• Chen, L.Y., et al., 2010. Chronic ethanol feeding impairs AMPK and MEF2 expression and is associated with GLUT4 decrease in rat myocardium. Experimental & molecular medicine, 42 (3), 205–215.
   PubMed Web of Science ®Google Scholar
• Cheung, P.C.F., et al., 2000. Characterization of AMP-activated protein kinase γ -subunit isoforms and their role in AMP binding. Biochemical journal, 346 (3), 659–669.
   PubMedGoogle Scholar
• Cho, H., et al., 2001. Insulin Resistance and a Diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science (New York, N.Y.), 292 (5522), 1728–1731.
   PubMed Web of Science ®Google Scholar
• Choudhary, A., et al., 2015. Qualitative and quantitative analysis of Potentilla fulgens roots by NMR, matrix-assisted laser desorption/ionisation with time-of-flight MS, electrospray ionisation MS/MS and HPLC/UV. Phytochemical analysis : PCA, 26 (2), 161–170.
   PubMed Web of Science ®Google Scholar
• Coughlan, K.A., et al., 2014. AMPK activation: a therapeutic target for type 2 diabetes? Diabetes, metabolic syndrome and obesity : targets and therapy, 7, 241–253.
   PubMedGoogle Scholar
• Cusi, K. and Defronzo, R.A., 1998. Metformin: a review of its metabolic effects. Diabetes reviews, 6, 89–131.
   Google Scholar
• Floch, J.P., et al., 1990. Blood glucose area under the curve: methodological aspects. Diabetes care, 13 (2), 172–175.
   PubMed Web of Science ®Google Scholar
• Foretz, M., et al., 2005. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes, 54 (5), 1331–1339.
   PubMed Web of Science ®Google Scholar
• Foretz, M., et al., 2010. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. The journal of clinical investigation, 120 (7), 2355–2369.
   PubMed Web of Science ®Google Scholar
• Garofalo, R.S., et al., 2003. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. The journal of clinical investigation, 112 (2), 197–208.
   PubMed Web of Science ®Google Scholar
• Gosmanov, A.R., Schneider, E.G., and Thomason, D.B., 2003. NKCC activity restores muscle water during hyperosmotic challenge independent of insulin, ERK, and p38 MAPK. American journal of physiology. regulatory, integrative and comparative physiology, 284 (3), R655–R666.
   PubMed Web of Science ®Google Scholar
• Hansen, P.A., et al., 1998. A high fat diet impairs stimulation of glucose transport in muscle. Functional evaluation of potential mechanisms. The journal of biological chemistry, 273 (40), 26157–26163.
   PubMed Web of Science ®Google Scholar
• Harborne, J. B., 1998. Phytochemical methods. London: Chapman and Hall.
   Google Scholar
• Hardie, D.G., 2011. Energy sensing by the AMP-activated protein kinase and its effects on muscle metabolism. The proceedings of the Nutrition Society, 70 (1), 92–99.
   PubMed Web of Science ®Google Scholar
• Huang, X., et al., 2018. The PI3K/AKT pathway in obesity and type 2 diabetes. International journal of biological sciences, 14 (11), 1483–1496.
   PubMed Web of Science ®Google Scholar
• Jørgensen, S.B., et al., 2007. Role of AMPK2 in basal training and AICAR-induced GLUT4, hexoinase II, and mitochondrial protein expression in mouse muscle. American journal of physiology. Endocrinology and metabolism, 292, 331–339.
   PubMed Web of Science ®Google Scholar
• Kayang, H., et al., 2005. Medinal plants of Khasi Hills of Meghalaya. Acta horticulturae, 675 (675), 75–80.
   Google Scholar
• Keskin, M., et al., 2005. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics, 115 (4), e500–e503.
   PubMed Web of Science ®Google Scholar
• Kothari, V., Galdo, J.A., and Mathews, S.T., 2016. Hypoglycemic agents and potential anti-inflammatory activity. Journal of inflammation research, 9, 27–38.
   PubMed Web of Science ®Google Scholar
• Lehrke, M. and Lazar, M.A., 2005. The many faces of PPARgamma. Cell, 123 (6), 993–999.
   PubMed Web of Science ®Google Scholar
• Liu, M., et al., 2010. Astragalus polysaccharide improves insulin sensitivity in KKAy mice: regulation of PKB/GLUT4 signaling in skeletal muscle. Journal of ethnopharmacology, 127 (1), 32–37.
   PubMed Web of Science ®Google Scholar
• Livak, K.J. and Schmittgen, T.D., 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods (San Diego, Calif.), 25 (4), 402–408.
   PubMed Web of Science ®Google Scholar
• Lizunov, V.A., et al., 2013. Insulin regulates Glut4 confinement in plasma membrane clusters in adipose cells. PLOS one, 8 (3), e57559.
   PubMed Web of Science ®Google Scholar
• Nelson, D. and Cox, M., 2004. Lehninger principles of biochemistry. 4th ed. New York: Freeman.
   Google Scholar
• Mackenzie, R.W. and Elliott, B.T., 2014. Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes. Diabetes, metabolic syndrome and obesity : targets and therapy, 7, 55–64.
   PubMedGoogle Scholar
• Madiraju, A.K., Erion,  et al., 2014. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature, 510 (7506), 542–546.
   PubMed Web of Science ®Google Scholar
• Meyer, M.M., et al., 2002. Troglitazone treatment increases protein kinase B phosphorylation in skeletal muscle of normoglycemic subjects at risk for the development of type 2 diabetes. Diabetes, 51 (9), 2691–2697.
   PubMed Web of Science ®Google Scholar
• Miura, T., et al., 2001. Impairment of insulin-stimulated GLUT4 translocation in skeletal muscle and adipose tissue in the Tsumura Suzuki obese diabetic mouse: a new genetic animal model of type 2 diabetes. European journal of endocrinology, 145 (6), 785–790.
   PubMed Web of Science ®Google Scholar
• Musi, N., et al., 2002. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes, 51 (7), 2074–2081.
   PubMed Web of Science ®Google Scholar
• O’Neill, H.M., 2013. AMPK and exercise: glucose uptake and insulin sensitivity. Diabetes & metabolism journal, 37, 1–21.
   PubMedGoogle Scholar
• Olabi, B. and Bhopal, R., 2009. Diagnosis of diabetes using the oral glucose tolerance test. BMJ (Clinical research ed.), 339, b4354
   PubMedGoogle Scholar
• Rice, S., et al., 2011. Action of metformin on the insulin-signaling pathway and on glucose transport in human granulosa cells. The Journal of clinical endocrinology and metabolism, 96 (3), E427–E435.
   PubMed Web of Science ®Google Scholar
• Richardson, J.M., et al., 1991. Differential regulation of glucose transporter activity and expression in red and white skeletal muscle. The journal of biological chemistry, 266 (19), 12690–12694.
   PubMed Web of Science ®Google Scholar
• Rizvi, S.M., Shakil, S., and Haneef, M., 2013. A simple click by click protocol to perform docking: Autodock 4.2 made easy for the non-bioinformatics. EXCLI Journal, 12, 831–857.
   PubMed Web of Science ®Google Scholar
• Ruderman, N.B., et al., 2013. AMPK, insulin resistance, and the metabolic syndrome. The journal of clinical investigation, 123 (7), 2764–2772.
   PubMed Web of Science ®Google Scholar
• Ruderman, N. and Prentki, M., 2004. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nature reviews. Drug discovery, 3 (4), 340–351.
   PubMed Web of Science ®Google Scholar
• Saio, V., et al., 2016. Amelioration of age-dependent increase in oxidative stress markers in male mice by extract of Potentilla fulgens. Redox report : communications in free radical research, 21 (3), 130–138.
   PubMed Web of Science ®Google Scholar
• Saio, V., Syiem, D., and Sharma, R., 2009. In vitro study of the antioxidant potential of some traditionally used medicinal plants of north-east India and assessment of their total phenolic content. Pharmacologyonline, 3, 952–965.
   Google Scholar
• Sivitz, W.I., et al., 1989. Regulation of glucose transporter messenger RNA in insulin-deficient states. Nature, 340 (6228), 72–74.
   PubMed Web of Science ®Google Scholar
• Steinberg, G.R. and Kemp, B.E., 2009. AMPK in health and disease. Physiological reviews, 89 (3), 1025–1078.
   PubMed Web of Science ®Google Scholar
• Syiem, D., et al., 2002. Hypoglycemic effects of Potentilla fulgens L. in normal and alloxan-induced diabetic mice. Journal of ethnopharmacology, 83 (1-2), 55–61.
   PubMed Web of Science ®Google Scholar
• Syiem, D., et al., 2003. Anti tumour activity crude root extract of Potentilla fulgens. Indian drugs, 40, 124–127.
   Google Scholar
• Syiem, D., Khup, P.Z., and Syiem, A.B., 2009. Effects of Potentilla fulgens Linn. on carbohydrate and lipid profiles in diabetic mice. Pharmocologyonline, 2, 787–795.
   Google Scholar
• Syiem, D. and Majaw, S., 2010. Effect of Potentilla fulgens L. aldose reductase activity of normal and diabetic mice. Inventi Rapid: Ethnopharmacology, 1, 13.
   Google Scholar
• Tangpu, V., Deori, K., and Yadav, A.K., 2014. Evaluation of safety and protective effects of Potentilla fulgens root extract in experimentally induced diarrhea in mice. Journal of intercultural ethnopharmacology, 3 (3), 103–108.
   PubMedGoogle Scholar
• Tomczyk, M., Wiater, A., and Pleszczyńska, M., 2011. In vitro anticariogenic effects of aerial parts of Potentilla recta and its phytochemical profile. Phytotherapy research : PTR, 25 (3), 343–350.
   PubMed Web of Science ®Google Scholar
• Umpierrez, G., et al., 1995. Diabetic ketoacidosis in obese African-Americans. Diabetes, 44 (7), 790–795.
   PubMed Web of Science ®Google Scholar
• Viollet, B., et al., 2009. AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta physiologica (Oxford, England), 196 (1), 81–98.
   PubMed Web of Science ®Google Scholar
• Winder, W.W., 2008. Can patients with type 2 diabetes be treated with 5'-AMP-activated protein kinase activators? Diabetologia, 51 (10), 1761–1764.
   PubMed Web of Science ®Google Scholar
• Woods, A., et al., 1996. Characterization of AMP-activated protein kinase beta and gamma subunits. Assembly of the heterotrimeric complex in vitro. The journal of biological chemistry, 271 (17), 10282–10290.
   PubMed Web of Science ®Google Scholar
• Yamauchi, T., et al., 2001. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. The journal of biological chemistry, 276 (44), 41245–41254.
   PubMed Web of Science ®Google Scholar
• Zang, M., et al., 2004. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. The journal of biological chemistry, 279 (46), 47898–478905.
   PubMed Web of Science ®Google Scholar
• Zierath, J.R., et al., 2000. Insulin action and insulin resistance in human skeletal muscle. Diabetologia, 43, 821–835.
   Google Scholar